The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

View Congress Resources by Therapeutic Area
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted. Audio abstracts are generated using text-to-speech software and contain an audio version of the abstract that was submitted and accepted as part of the official conference materials.
Showing 6 of 64 results
Sort by date: Descending
Encores: Not included
Sleep-wake disorders
SLEEP 2026 POSTER
Improvement in Sleepiness With Once-Nightly Sodium Oxybate in People With Narcolepsy Type 1 and Narcolepsy Type 2: A Specialty Pharmacy Data Analysis
AUTHOR(S)

Sarah Meskill, MD1; Laura B. Herpel, MD2,3; Michael J. Thorpy, MD4; Chad M. Ruoff, MD5; Diana Carino, PharmD, CSP, AAHIVP6; Erin Buysman, MS7; Michelle Vu, PharmD, MPH7; Brian Abaluck, MD8; Jennifer Gudeman, PharmD9,a
 

View poster
Sleep-wake disorders
Sleep-wake disorders
SLEEP 2026 POSTER
Oxybate Treatment Patterns in Patients With Narcolepsy: Cohort Data From Mayo Clinic and Duke Health
AUTHOR(S)

Melissa C. Lipford, MD1; Marjorie Soltis, MD2; Allison Smither, PhD3,a; Jennifer Gudeman, PharmD4,a; Lois E. Krahn, MD5

View poster
Sleep-wake disorders
Sleep-wake disorders
SLEEP 2026 POSTER
Sleepiness Improvement With Once-Nightly Sodium Oxybate in Patients With and Without Prior Twice-Nightly Oxybate Use: Specialty Pharmacy Data Analysis
AUTHOR(S)

Laura B. Herpel, MD1,2; Michael J. Thorpy, MD3; Sarah Meskill, MD4; Chad M. Ruoff, MD5; Erin Buysman, MS6; Diana Carino, PharmD, CSP, AAHIVP7; Michelle Vu, PharmD, MPH6; Brian Abaluck, MD8; Jennifer Gudeman, PharmD9,a
 

View poster
Sleep-wake disorders
Sleep-wake disorders
SLEEP 2026 POSTER
Brilliance NT1: Study Design and Methods for Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating Alixorexton in Patients With Narcolepsy Type 1
AUTHOR(S)

Giuseppe Plazzi,1,2 Emmanuel Mignot,3 Richard K. Bogan,4 Ronald R. Grunstein,5,6 Gert Jan Lammers,7,8 David T. Plante,9 Rafael del Río Villegas,10,11 Hailu Chen,12 Bikram Kabir,12 Juan Chavez,12 Bhaskar Rege,12 Craig Hopkinson,12 Julie Himes,12 Yves Dauvilliers13
 

View poster
Sleep-wake disorders
Sleep-wake disorders
SLEEP 2026 POSTER
Impact of Sex and Race on Treatment of Narcolepsy: A Claims Database Analysis
AUTHOR(S)

Rakesh Bhattacharjee, MD1; Alec B. Platt, MD, MSCE2; Cecile Martin, FNP-BC, MS, RN3,4; Jennifer Gudeman, PharmD5,a; Johanna Hertel, PhD6; Brian Abaluck, MD6
 

View poster
Sleep-wake disorders
Sleep-wake disorders
SLEEP 2026 POSTER
Nighttime Symptom Experience and Treatment Challenges: Perspectives From People With Narcolepsy
AUTHOR(S)

Luis E. Ortiz, MD1; Maggie Lavender, MSN, RN, FNP-C2,3; Anne Marie Morse, DO4; Beth Schneider, BA5; Matthew Horsnell, BS6; Dan Liss7; Shawn Kuczenski8; Jennifer Gudeman, PharmD9,a

View poster
Sleep-wake disorders